Quality of life in patients with malignant ascites and after treatment with catumaxomab: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesi…
B Schmalfeldt, K Seck, AK Gonschior, H Gilet, M Heiss, M Hennig, M Moehler, E Schulze, P Wimberger, SL Parsons · Geburtshilfe und Frauenheilkunde · 2012 · Heft 04
Bibliografische Angaben
Zusammenfassung
Fragestellung: Patients suffering from malignant ascites (MA) experience burdensome symptoms and an impaired quality of life (QoL) So far, therapeutic options are limited. The trifunctional antibody catumaxomab is approved for the treatment of MA. Its superiority over paracentesis including a positive trend in overall survival has been demonstrated in a pivotal study. The objective of this analysis was to compare ascites symptoms and QoL of patients treated with catumaxomab or paracentesis. Methode: QoL and ascites symptoms were assessed for patients with MA randomized to catumaxomab (N=170) and paracentesis (N=…
